Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
The recommended starting dose is 10 mg once daily for patients who weigh 20 kg to less than 35 kg and 20 mg once daily for patients who weigh at least 35 kg. After 2 weeks, the dose can be increased to a maximum of 20 mg once daily in those who weigh less than 35 kg and 40 mg once daily in those who weigh at least 35 kg.
Improved sickle cell disease in children associated with hydroxyurea treatment
November 27th 2023A recent study underscores the significant disease burden in children with sickle cell disease, urging consideration for earlier and higher-dose hydroxyurea treatment to alleviate morbidity, especially in those with HbSS/Sβ0 thalassemia.
2 Clarke Drive
Cranbury, NJ 08512